1. A 34-year-old agricultural worker collapses in a field. Paramedics find him with pinpoint pupils, profuse salivation and lacrimation, vomiting, diarrhea, bradycardia of 38 bpm, severe bronchospasm, and diffuse muscle fasciculations. He is confused and has generalized weakness. The local poison control center identifies the likely exposure as chlorpyrifos, an organophosphate pesticide. Using the full mechanistic framework of cholinergic receptor pharmacology, identify which receptor subtype mediates each cluster of findings and explain why the fasciculations must be addressed differently from the secretory and cardiovascular features.

• A) All findings are mediated by M3 muscarinic receptors — pinpoint pupils (M3 sphincter pupillae constriction), bradycardia (M3 SA node), salivation and lacrimation (M3 glands), bronchospasm (M3 smooth muscle), fasciculations (M3 at the motor endplate), and confusion (M3 CNS); atropine at high doses reverses all findings by blocking M3 everywhere; fasciculations resolve at the same dose as bronchospasm because both are mediated by M3 at their respective effector sites.
• B) Bradycardia is mediated by M2 receptors; glandular secretions and bronchospasm are mediated by M3 receptors; fasciculations are mediated by M1 receptors at the NMJ in a slow modulatory capacity; confusion reflects ganglionic M1 overactivation; atropine reverses M1, M2, and M3 effects equally and also reverses fasciculations since M1 at the NMJ is the nicotinic subtype responsible for fast EPP generation in this context.
• C) Pinpoint pupils, bronchospasm, bradycardia, salivation, and lacrimation all reflect muscarinic M3/M2 receptor overactivation from ACh accumulation; fasciculations and weakness reflect nicotinic receptor overactivation at the NMJ from the same ACh accumulation; atropine competitively blocks all muscarinic and nicotinic receptor types simultaneously, reversing the entire syndrome at sufficient dose; pralidoxime is unnecessary because atropine at high enough concentrations will reverse fasciculations and flaccid paralysis by also blocking nicotinic receptors.
• D) All findings are explained by direct organophosphate agonism at muscarinic receptors — the drug itself activates M2, M3, and nicotinic receptors as a partial agonist; AChE is not involved because chlorpyrifos acts as a direct receptor agonist rather than an enzyme inhibitor; pralidoxime reverses the syndrome by competitively displacing chlorpyrifos from receptor binding sites rather than by reactivating AChE.
• E) Chlorpyrifos irreversibly inhibits AChE, causing ACh to accumulate at all cholinergic synapses. Muscarinic features (bradycardia via M2 at the SA and AV nodes; bronchospasm, increased secretions, and miosis via M3 at smooth muscle and glands) are reversed by atropine, a competitive muscarinic antagonist. Fasciculations arise from persistent ACh-induced depolarization at NMJ nAChRs ((α1)₂β1δε), with initial repetitive firing followed by depolarizing blockade causing flaccid paralysis and respiratory failure — these nicotinic features are outside atropine's pharmacodynamic scope and require pralidoxime (to regenerate phosphorylated AChE before aging) plus mechanical ventilation; benzodiazepines address the CNS seizure activity driven by excess ACh at central nAChRs and muscarinic receptors; the combination of atropine for muscarinic features and pralidoxime for enzyme reactivation is the mechanistically complete antidotal strategy.

2. A 67-year-old man with moderate Alzheimer's disease is started on donepezil 5 mg at bedtime. Three weeks later, his caregiver reports improved word-finding and less confusion during the day, but the patient has developed new bradycardia (heart rate 48 bpm), vivid dreams, and early-morning nausea. Using the pharmacology of AChE inhibition and muscarinic receptor distribution, explain why the therapeutic benefit and each adverse effect occur, and why the drug is given at bedtime.

• A) Donepezil improves cognition by selectively activating M1 receptors in the hippocampus; it has no effect on AChE and works entirely through direct M1 agonism; bradycardia is a direct M2 agonist effect at the SA node; nausea reflects M3 activation in the GI tract; vivid dreams occur because donepezil activates REM sleep pathways through direct nicotinic α4β2 agonism; bedtime dosing is used to maximize the nicotinic REM effect during sleep when α4β2 receptors are most abundant.
• B) Donepezil inhibits AChE in both the CNS and periphery, increasing ACh at all cholinergic synapses. Cognitive improvement reflects enhanced ACh at cortical M1 receptors and hippocampal M1/nAChRs (supporting synaptic plasticity and attention circuits of the basal forebrain projections). Bradycardia reflects peripheral ACh accumulation at cardiac M2 receptors on the SA node (slowing the I_f pacemaker current and activating IKACh/GIRK channels). Nausea arises from M3/M1 receptor activation in the GI tract increasing motility and stimulating the chemoreceptor trigger zone centrally. Vivid dreams occur because increased ACh during REM sleep (when cholinergic activity is physiologically high) produces cholinergic over-drive in the pontine REM-on circuits. Bedtime dosing exploits the peak drug effect coinciding with the sleep period when peripheral side effects (nausea) are less noticed and the REM-related vivid dreams, while a side effect, are tolerable; also, peak drug levels during sleep may minimize daytime GI adverse effects.
• C) Donepezil's therapeutic benefit and all adverse effects are mediated exclusively through nicotinic α7 receptors — M1 and M2 muscarinic receptors are not involved; bradycardia reflects α7 activation on the SA node causing membrane hyperpolarization through a calcium-dependent mechanism; nausea reflects α7 activation in the area postrema; vivid dreams reflect α7-mediated REM sleep potentiation; bedtime dosing is chosen to minimize nicotinic stimulation during waking hours.
• D) Donepezil inhibits AChE selectively in the brain without any peripheral effects; bradycardia and nausea arise from dopaminergic cross-talk — increased CNS ACh from donepezil stimulates dopamine release, which acts at D2 receptors in the cardiac conduction system and area postrema respectively; vivid dreams reflect dopamine-induced activation of the substantia nigra during sleep; bedtime dosing prevents daytime dopaminergic adverse effects by confining peak drug levels to nighttime.
• E) The cognitive benefit of donepezil occurs through M3-mediated increases in cerebral blood flow rather than direct synaptic enhancement; M3 receptors on cerebrovascular smooth muscle produce vasodilation and increased oxygen delivery; bradycardia reflects a baroreceptor reflex response to the increased cerebrovascular blood flow; nausea is caused by cerebrovascular dilation acting on the vestibular apparatus; vivid dreams reflect the pharmacokinetic accumulation of an active metabolite of donepezil that crosses the BBB at night when melatonin alters BBB permeability.

3. A 52-year-old woman with myasthenia gravis (MG) is admitted with worsening weakness, dysphagia, and respiratory distress. She has been on pyridostigmine 60 mg every 4 hours. The neurology team debates whether she is in myasthenic crisis (undertreated MG with insufficient AChE inhibition) or cholinergic crisis (excess AChE inhibition causing depolarizing NMJ blockade). Using the pharmacodynamic differences between these two states at the NMJ, describe how each crisis produces weakness and how you would clinically distinguish between them.

• A) Myasthenic crisis and cholinergic crisis cannot be distinguished at the bedside because both produce identical flaccid weakness and identical EMG findings; the Tensilon test is the gold standard for distinguishing them and is always safe to perform even in respiratory distress because edrophonium has such a short duration of action; if the test improves strength, the diagnosis is myasthenic crisis; if it causes no change, the diagnosis is cholinergic crisis; worsening after edrophonium is pharmacologically impossible because edrophonium has pure competitive antagonist activity.
• B) Myasthenic crisis is caused by excess AChE enzyme activity that degrades ACh too rapidly; cholinergic crisis is caused by insufficient AChE inhibition; in myasthenic crisis, giving more pyridostigmine is harmful because it further increases AChE activity; in cholinergic crisis, giving atropine reverses the weakness directly by competing with the excess ACh at the NMJ nAChRs; the Tensilon test is contraindicated in both crises because edrophonium activates nAChRs directly, worsening neuromuscular block in both situations.
• C) Myasthenic crisis results from autoantibody-mediated destruction of nAChRs progressing to complete receptor loss; cholinergic crisis results from accumulated ACh destroying nAChRs through receptor internalization; both crises produce weakness by reducing total nAChR density; the distinction is that myasthenic crisis involves gradual receptor loss while cholinergic crisis involves acute receptor internalization; pyridostigmine dose adjustment is not useful because receptor density cannot be restored pharmacologically on an acute basis.
• D) Myasthenic crisis: worsening autoimmune destruction of postsynaptic nAChRs reduces EPP amplitude below threshold; each ACh quantum releases normal amounts of ACh, but fewer functional receptors mean insufficient depolarization; weakness worsens without cholinergic symptoms. Cholinergic crisis: excess AChE inhibition causes ACh accumulation at the NMJ, persistently depolarizing the endplate, causing sodium channel inactivation and failure of action potential propagation (Phase II depolarizing block), producing flaccid weakness; cholinergic symptoms (miosis, bradycardia, excess secretions, fasciculations) accompany the weakness and distinguish this state from myasthenic crisis. Clinical distinction: the presence of muscarinic features (SLUDGE, bradycardia, miosis) alongside weakness strongly suggests cholinergic crisis; their absence suggests myasthenic crisis; the edrophonium (Tensilon) test can help — brief improvement indicates myasthenic crisis; worsening (or no change) with worsening cholinergic symptoms indicates cholinergic crisis; it should be used cautiously with atropine available and should not be performed in severe respiratory compromise where any worsening is dangerous.
• E) In myasthenic crisis, autoantibodies against the AChE enzyme reduce AChE activity at the NMJ, causing ACh accumulation identical to pyridostigmine overdose; the distinction between myasthenic and cholinergic crisis is therefore not based on receptor pharmacodynamics but on the source of AChE inhibition (autoimmune versus drug-induced); both crises are treated identically with atropine to block the accumulated ACh at muscarinic receptors and pralidoxime to regenerate drug-inhibited AChE; the Tensilon test distinguishes them by the source of AChE inhibition rather than by pharmacodynamic consequences.

4. A 28-year-old man with no prior medical history undergoes elective laparoscopic cholecystectomy. He receives succinylcholine for rapid sequence intubation and is paralyzed for 45 minutes. After the procedure, reversal with neostigmine and glycopyrrolate is attempted but the patient cannot sustain a head lift and remains on the ventilator for 6 hours until spontaneous recovery. His serum potassium was 4.1 mEq/L. A genetic analysis ordered after the event reveals a homozygous dibucaine-resistant BuChE variant. Using the pharmacology of neuromuscular transmission, explain the mechanism of his prolonged paralysis and why neostigmine failed to accelerate recovery.

• A) The patient has pseudocholinesterase (BuChE) deficiency from a dibucaine-resistant genetic variant; BuChE normally hydrolyzes succinylcholine in the plasma within 3–5 minutes; with absent BuChE activity, succinylcholine is not degraded in plasma, maintaining high systemic concentrations that continuously diffuse to the NMJ and replenish the persistent endplate depolarization (Phase I block); neostigmine failed to reverse paralysis for two mechanistically distinct reasons: (1) neostigmine inhibits AChE, not BuChE — it cannot accelerate succinylcholine hydrolysis; and (2) by inhibiting AChE, neostigmine increases ACh at the NMJ, adding cholinergic depolarizing activity on top of the pre-existing succinylcholine-driven depolarization, potentially prolonging or deepening the depolarizing block; recovery required waiting for succinylcholine hydrolysis by alternative routes (plasma esterases, spontaneous Hofmann elimination at alkaline pH) and eventual AChE-mediated clearance of any transition to Phase II block.
• B) The prolonged paralysis is due to Phase II block that developed from sustained succinylcholine exposure; Phase II block resembles non-depolarizing block and is reversed by AChE inhibitors; neostigmine failed because it was given too early before Phase II block was fully established; waiting an additional 15 minutes before re-administering neostigmine would have successfully reversed the paralysis; the BuChE deficiency is irrelevant because Phase II block is independent of succinylcholine plasma concentration.
• C) BuChE deficiency prevents acetylcholine hydrolysis at the NMJ because BuChE is the predominant synaptic esterase at the motor endplate in normal individuals; without BuChE, ACh accumulates in the synaptic cleft during succinylcholine administration, causing excessive endplate depolarization; neostigmine failed because it inhibits only the neuronal AChE isoform while BuChE is the therapeutically relevant esterase for NMJ reversal; fresh frozen plasma containing functional BuChE would have immediately reversed the block.
• D) The prolonged paralysis resulted from succinylcholine activating Phase II block through a calcium-dependent mechanism that requires BuChE for termination; BuChE transports calcium out of the synaptic cleft after succinylcholine-mediated depolarization; without BuChE, cleft calcium accumulates, maintaining sodium channel inactivation and endplate depolarization; neostigmine failed because it requires BuChE to be present to exert its reversal effect; giving calcium gluconate IV would have terminated the block by restoring normal cleft calcium dynamics.
• E) The prolonged block occurred because the patient's dibucaine-resistant BuChE variant has enhanced rather than reduced succinylcholine affinity; the variant enzyme binds succinylcholine but cannot hydrolyze it, forming a stable enzyme-drug complex that sequestrates succinylcholine away from plasma; succinylcholine is then slowly released over hours from this complex, producing sustained plasma concentrations; neostigmine reversed the AChE component of the block but the BuChE-sequestrated succinylcholine reservoir continued to reload the NMJ; treatment required dibucaine to competitively displace succinylcholine from the BuChE complex.

5. A 19-year-old woman presents to the emergency department with a dry flushed face, dilated pupils, heart rate of 128 bpm, urinary retention, absent bowel sounds, and rapidly worsening agitation and confusion. Her friends report she took several "allergy pills" from her grandmother's medicine cabinet before a party. A urine drug screen is negative for common drugs of abuse. The emergency physician suspects anticholinergic toxidrome. Using muscarinic receptor subtype pharmacology, explain each physical finding, why the skin is dry and flushed rather than moist, and how to distinguish this toxidrome from sympathomimetic excess.

• A) The dry flushed skin is caused by M1 receptor blockade in sweat glands causing anhidrosis, combined with M2 receptor blockade in cutaneous vasomotor neurons causing vasodilation; tachycardia is caused by M2 blockade in the SA node; mydriasis is caused by M1 blockade in the ciliary ganglion; the toxidrome is distinguished from sympathomimetic excess by the presence of urinary retention and absent bowel sounds, which are caused by M3 blockade in the bladder and GI tract — sympathomimetics do not affect these systems.
• B) All findings reflect M3 muscarinic blockade exclusively — M3 receptors mediate all organ responses in the anticholinergic syndrome; the flushed dry skin is caused by M3 blockade in eccrine sweat glands and cutaneous vascular smooth muscle simultaneously; the toxidrome is distinguished from sympathomimetic excess solely by the dilated pupils — sympathomimetics produce miosis via α1 receptor-mediated iris dilator stimulation while anticholinergics produce mydriasis by blocking the M3 iris sphincter.
• C) Anticholinergic toxidrome results from muscarinic blockade across multiple receptor subtypes. Dry mouth and anhidrosis: M3 blockade in exocrine glands (salivary, eccrine sweat glands) eliminates parasympathetic secretomotor drive; sweat glands are uniquely innervated by sympathetic cholinergic fibers acting on M3 receptors — their blockade causes anhidrosis and heat accumulation → cutaneous vasodilation (reflex or direct M3-mediated) accounts for flushing. Tachycardia: M2 blockade at the SA node removes parasympathetic braking, allowing sympathetic tone to accelerate the pacemaker. Mydriasis: M3 blockade of the iris sphincter pupillae (circular muscle) eliminates parasympathetic pupilloconstriction; sympathetic α1-mediated dilator pupillae is unopposed. Urinary retention: M3 blockade of detrusor smooth muscle prevents bladder contraction. Ileus: M3/M1 blockade of GI smooth muscle and enteric ganglia eliminates propulsive motility. CNS: M1 blockade in cortex and hippocampus → agitation, confusion, delirium. Distinction from sympathomimetics: sympathomimetic excess (cocaine, amphetamines) produces tachycardia, mydriasis, and agitation but also diaphoresis (profuse sweating from sympathetic cholinergic fiber activation) and hypertension; anticholinergic toxidrome produces anhidrosis (dry skin) and more commonly hyperthermia from impaired sweating rather than the wet diaphoretic state of sympathomimetic excess.
• D) The flushed dry skin occurs because M2 receptor blockade in cutaneous arterioles causes vasodilation while simultaneous α1 sympathetic activation (from M2 blockade in ganglionic neurons) causes vasoconstriction in deeper vessels, shunting blood to the skin; the net effect is cutaneous flushing with dry skin; sympathomimetic excess is distinguished from anticholinergic toxidrome by the pattern of pupillary response — sympathomimetics cause mydriasis via α1 receptor activation of the iris dilator, producing an irregular elliptical pupil, while anticholinergics produce a perfectly round dilated pupil through M3 iris sphincter blockade.
• E) The clinical features are caused entirely by nicotinic receptor blockade, not muscarinic blockade — the allergy pills likely contained a ganglionic blocker that blocked both sympathetic and parasympathetic ganglia; tachycardia and mydriasis reflect loss of parasympathetic ganglionic drive; urinary retention and ileus reflect loss of both sympathetic and parasympathetic ganglionic drive to the bladder and GI tract; physostigmine reverses the syndrome by activating nicotinic receptors post-ganglionically rather than by any muscarinic mechanism.

6. A 71-year-old man with COPD and atrial fibrillation (AF) with rapid ventricular response is admitted with an acute exacerbation. His medications include tiotropium (long-acting muscarinic antagonist) for COPD and he is started on digoxin for rate control of his AF. Three days into admission, he develops worsening bronchospasm. The team notes that his digoxin level is 1.8 ng/mL (therapeutic), and his tiotropium inhaler technique is confirmed adequate. A pharmacology consultant is asked to explain the possible pharmacodynamic interaction between digoxin and tiotropium that could produce worsening bronchospasm despite appropriate LAMA therapy.

• A) Digoxin inhibits Na⁺/K⁺-ATPase in bronchial smooth muscle, directly causing smooth muscle depolarization and contraction; this effect is additive to any residual M3 receptor activity not blocked by tiotropium; the interaction is pharmacokinetic — digoxin displaces tiotropium from plasma protein binding sites, reducing tiotropium free concentration at bronchial M3 receptors; increasing the tiotropium dose would restore adequate receptor coverage.
• B) Digoxin enhances sympathetic tone through its central vagomimetic properties; increased sympathetic activity at β₂ adrenoceptors paradoxically activates Gαs-driven bronchoconstriction at high sympathetic stimulation levels; tiotropium cannot block this pathway because it only acts at muscarinic receptors; adding a β₂ antagonist paradoxically would improve the bronchoconstriction by preventing the paradoxical β₂-mediated constriction.
• C) The worsening bronchospasm reflects tiotropium-induced bronchoconstriction through its M2 autoreceptor blockade — by blocking prejunctional M2 autoreceptors on airway parasympathetic terminals, tiotropium disinhibits ACh release and increases cholinergic tone; this tiotropium-driven excess ACh then activates digoxin-sensitized M3 receptors on airway smooth muscle; digoxin increases M3 receptor sensitivity through Na⁺/K⁺-ATPase inhibition in the airway smooth muscle cell that alters intracellular calcium handling, potentiating M3-mediated contraction; the solution is to switch to ipratropium which has better M2/M3 balance.
• D) Digoxin is a positive inotrope and rate-controlling agent; at therapeutic levels it increases vagal (parasympathetic) tone centrally through its effects on the nucleus tractus solitarius; increased central vagal output augments ACh release from parasympathetic fibers innervating the bronchi; if tiotropium's bronchial M3 blockade is incomplete at peak drug concentration — or during trough periods between once-daily doses — this digoxin-enhanced vagal ACh release can exceed the receptor blockade capacity of tiotropium, producing breakthrough bronchoconstriction particularly late in the 24-hour dosing interval; confirming the timing of the inhaler dose relative to symptom onset and ensuring adherence to once-daily dosing is clinically important.
• E) Digoxin enhances parasympathetic (vagal) tone by sensitizing cardiac baroreceptors and augmenting vagal efferent output centrally; in the lungs, enhanced vagal tone increases ACh release from parasympathetic bronchial nerves; tiotropium's bronchodilatory benefit depends on blocking this vagally-driven ACh at M3 receptors; if digoxin significantly increases vagal ACh release beyond what the once-daily tiotropium dose can continuously suppress — especially during pharmacokinetic trough periods — breakthrough bronchoconstriction can emerge; additionally, digoxin-related gastrointestinal nausea may impair inhaler use adherence; the clinical solution is to verify the dosing schedule, check tiotropium inhalation technique, and consider whether digoxin dose reduction or substitution with another rate-control agent would reduce the vagotonic contribution to bronchospasm.